Exciting News! Azista Bhutan is thrilled to introduce our newest product to the market - LANOL 650 Paracetamol Tablets IP 650 MG!
We are incredibly proud to share that our dedicated team at ABHL, Bhutan plant, has successfully completed the development and packaging of this fantastic addition to our product range. The LANOL 650 tablets are now ready to provide effective relief and comfort to those in need.
With the utmost care and precision, we have crafted LANOL 650 to ensure the highest quality standards, offering you a reliable and trusted solution for your health needs.
Whether it's for a headache, fever, or mild pain, LANOL 650 is here to support you through life's little bumps.
At Azista Bhutan, we strive to continually enhance our product offerings to better serve our valued customers. Your well-being is our top priority, and we're committed to delivering safe and effective pharmaceutical solutions.
We would like to extend our heartfelt gratitude to our amazing team members whose dedication and hard work made this launch possible.
This milestone would not have been achieved without their unwavering support.
Thank you, our cherished customers and well-wishers, for your continued trust in us.
Stay tuned for more exciting updates from Azista Bhutan. Cheers to a healthier tomorrow!
Azista Bhutan, a leading pharmaceutical company, has made its first remarkable milestone by participating in the prestigious Bhutan Thematic Expo 2023. Here, the Bhutan Chamber of Commerce and Industry (BCCI) has launched four indigenous products. It also provided a platform for local entrepreneurs to display their local products. Azista Bhutan has grabbed the opportunity to exhibit its 32 pharmaceutical products, create awareness and understand the local market
The expo witnessed the presence of esteemed government representatives who addressed the gathering, highlighting the event's significance.
The expo proved a valuable platform for Azista Bhutan to interact with healthcare professionals, industry experts, and potential partners through engaging in discussions and exchanging ideas, nevertheless, Azista Bhutan strengthened its network and fostered meaningful collaborations within the healthcare sector.
The expo went for five days till June 26th and one of the key benefits of Azista Bhutan's participation in the expo was its enhanced visibility and brand recognition. Our company's presence at such a prominent event increased its reach and credibility among the medical community and the public.
This recognition is expected to drive further growth and solidify Azista Bhutan's position as a trusted pharmaceutical provider in Bhutan.
Our participation in the Bhutan Thematic Expo 2023 has given us an inspiration to propel the company towards even greater achievements. With its unwavering commitment to healthcare advancement, Azista Bhutan remains dedicated to improving the lives and well-being of the people it serves.
On this auspicious day, Azista Bhutan Healthcare Limited (ABHL) delivers two more products: FX24 120 mg -Fexofenadine Hydrochloride and EZEE 500 Azithromycin 500mg, in addition to the RHICET -Levocetirizine Hydrochloride and RHICET M - Montelukast 10 mg +Levocetirizine Hydrochloride 5mg that was delivered last month. In the preceding month, Lanol 500-Paracetamol was released. Today, ABHL has five medicines in the market. Many more products are already being developed and should be available to the customers soon. ABHL's goal is to ensure that Bhutanese citizens have access to high-quality, affordable, and timely medicines.
Azista Bhutan Healthcare Ltd. (ABHL) is FDI pharmaceutical company, a joint venture between Azista Industries Pvt. Ltd., Hyderabad, India and Druk Holding and Investments Ltd. (DHI), Bhutan with 72% and 28% shareholding, respectively. ABHL is located at Motanga Industrial Park, Samdrup Jongkhar, spread across 6.757 acres. ABHL is the first allopathic pharmaceutical manufacturer, packager, and distributor in Bhutan with the production capacity of General block 43.8 million capsules/tablets and Oncology block 16.8 million capsules/tablets per month. The Drug Regulatory Authority, RGoB, has certified ABHL for good manufacturing practice (GMP). Currently, the company has Technical Authorization to manufacture 213 goods (136 general medicines and 77 cancer drugs) across 17 distinct therapies. The oncology block is ready for production as well as packaging, while the general block is only ready for packaging. ABHL is currently working with distributors and retailers across the country, and has already received purchase orders for a few products from distributors. Oncology items will be manufactured in the coming days in response to demand from both domestic and international markets.
ABHL is donating 121,000 paracetamol 500mg (Brand:Lanol) tablets to the Ministry of Health, RGoB, which is the first product packaged at ABHL.
Mr. M Srinivasa Reddy, Director of our Azista Bhutan Healthcare Limited, inaugurated the new plant in Bhutan on Sunday, i.e., 9th of February 2020. The plant constructed at Motanga Industrial Park, Samdrup Jongkhar, in Bhutan. He launched the website www.azistabhutanhealthcare.com of our organization as part of the inaugural event. He also took part in the machine commissioning of our new plant. The inauguration happened amidst other leaders and employees of our Azista Bhutan Healthcare, the company which is a joint venture of Azista Industries Pvt. Ltd., Hyderabad and Druk Holding and Investments Ltd., RGoB, Bhutan.